Therapy Areas: Oncology
Gamma Knife Market Size to Reach USD 239.2m by 2025, Grand View Research Forecasts
13 September 2017 - - The global gamma knife market is expected to reach USD 239.2m by 2025, according to a new report by US-based market research and consulting company Grand View Research, Inc.

An increasing prevalence of cancer, brain tumors, and other neurological diseases, rising adoption of these instruments in surgery centers, growing preference for Minimally Invasive Surgeries, and technological advancements in the device are amongst few factors expected to drive the market.

Gamma knife therapy is used for treatment of various brain and neurological disorders such as brain tumors, brain metastases, epilepsy, and arteriovenous malformations.

Demand for these instruments in surgery centers is growing due to their various advantages such as safety, micro precision, lack of postsurgical complications, and lack of incisions.

Technological advancements have improved precision in surgery.

For instance, upgradation of Leksell Gamma Knife models U, B, C/4C, and Perfexion to Icon provided micro precision in surgery and boosted adoption of this device in surgery centers.

According to reports published by Elekta AB, approximately 70,000 patients undergo gamma knife surgery each year. This number is expected to increase over the forecast period owing to rising prevalence of target diseases and increasing preference for MIS.

In addition, growing demand for MIS over open surgeries is one of the key factors responsible for increasing adoption of this therapy.

Gamma knife treatment procedure results in fewer traumas and faster recovery as compared to open surgeries.

It helps reduce hospital stays, thus ensuring economic viability and reduction in medical expenses. Lack of incisions and postsurgical complications are key factors responsible for boosting demand for minimally invasive surgeries.

The Asia Pacific region is anticipated to witness lucrative growth over the next decade owing to rising incidence of cancer, developments in healthcare infrastructure, and rapid economic development across major emerging economies. It is expected to grow at a CAGR of around 4% over the forecast period.

Elekta AB is the only player operating in this market since Gamma Knife is a patent-protected trademark product of the company.